HFE H63D

HFE H63D — The Common Iron Variant

The HFE gene produces a protein that acts as an iron gatekeeper. It sits on
the surface of cells in the gut and liver, where it binds to
transferrin receptor 1 | TfR1: the main receptor cells use to take up iron
from the blood via iron-loaded transferrin and helps the body sense how
much iron is circulating. When iron levels are adequate, HFE triggers
production of hepcidin | A hormone produced by the liver that acts as the
master regulator of iron absorption — it blocks the iron exporter ferroportin
on gut cells, reducing dietary iron uptake, the master hormone that puts
the brakes on iron absorption. The H63D variant (rs1799945) is a C-to-G
change in exon 2 that swaps histidine for aspartic acid at position 63,
subtly weakening HFE's grip on transferrin receptor 1 and mildly blunting
the hepcidin response.

H63D is the second most common HFE variant after C282Y (rs1800562). While
C282Y is the primary driver of hereditary hemochromatosis — the most common
genetic disorder in people of Northern European descent — H63D has a milder
and more nuanced role. It is far more common (carried by roughly one in four
Europeans) yet far less likely to cause clinical iron overload on its own.

The Mechanism

The HFE protein is structurally similar to
MHC class I molecules | Major histocompatibility complex class I: the immune
system proteins that display fragments of internal proteins on the cell surface
for immune surveillance. It folds with beta-2 microglobulin and competes
with iron-loaded transferrin for binding to transferrin receptor 1 (TfR1). When
iron levels rise, HFE releases from TfR1 and instead binds TfR2, which
triggers a signaling cascade that upregulates hepcidin production. Hepcidin
then degrades ferroportin — the only known cellular iron exporter — on
intestinal enterocytes, effectively closing the gate on dietary iron absorption.

The H63D substitution sits in the alpha-1 domain of HFE, outside the primary
TfR1 binding interface (which involves the alpha-1/alpha-2 groove). It reduces
but does not abolish the interaction with TfR1. The result is a modest decrease
in hepcidin signaling: enough to slightly increase baseline iron absorption but
not enough to cause the dramatic iron loading seen with C282Y, which completely
disrupts HFE folding and surface expression.

The Evidence

The HFE gene was
discovered in 1996 | Feder JN et al. A novel MHC class I-like gene is mutated
in patients with hereditary haemochromatosis. Nat Genet, 1996
by Feder and colleagues, who found that 83% of hemochromatosis patients were
homozygous for C282Y. In the same study, H63D was identified on chromosomes
that carried hemochromatosis but not C282Y.

A pooled analysis of 14 case-control studies | Burke W et al. Contribution of
different HFE genotypes to iron overload disease: a pooled analysis. Genet Med,
2000 quantified the risk by
genotype: H63D homozygotes had an OR of 5.7 (95% CI 3.2-10.1) for iron
overload, while C282Y/H63D compound heterozygotes had OR 32 (95% CI 18.5-55.4)
— still far below C282Y homozygotes at OR 4,383. Simple H63D heterozygotes
had only a marginal elevation (OR 1.6, 95% CI 1.0-2.6).

A dedicated study of 170 H63D homozygotes | Kelley M et al. Iron overload is
rare in patients homozygous for the H63D mutation. Can J Gastroenterol Hepatol,
2014 found that while 29% had
elevated ferritin at baseline, only 6.7% developed documented iron overload at
follow-up, and just 1.7% progressed to iron overload-related disease.

For compound heterozygotes (C282Y + H63D), a
Newfoundland cohort study of 247 individuals | Power TE et al. C282Y/H63D
compound heterozygosity is a low penetrance genotype for iron overload-related
disease. J Can Assoc Gastroenterol,
2022 found that only 5.3%
developed iron overload-related disease at 10-year follow-up, with men at
higher risk (13.5% documented iron overload) than women (4.3%).

Beyond Iron: Hypertension and Athletic Performance

The H63D variant has associations beyond iron storage. The
ARIC study | Selvaraj S et al. HFE H63D Polymorphism and the Risk for
Systemic Hypertension. Hypertension,
2019 followed 10,902 white
participants and found that H63D carriers had higher systolic and diastolic
blood pressure, with a 2-4% (heterozygotes) and 4-7% (homozygotes) absolute
increase in hypertension risk. However, after 25 years of follow-up, there
was no increased risk of adverse cardiovascular events — the iron-mediated
blood pressure effect did not translate into heart attacks or strokes.

Intriguingly, the G allele appears to benefit endurance athletes. A
meta-analysis of five cohorts | Semenova EA et al. The association of HFE
gene H63D polymorphism with endurance athlete status and aerobic capacity.
Eur J Appl Physiol,
2020 found that CG/GG genotypes
were significantly overrepresented among elite endurance athletes (OR 1.96,
95% CI 1.58-2.45; P = 1.7 x 10^-9). Male athletes carrying the G allele also
had higher VO2max (66.3 vs 61.8 ml/min/kg). The proposed mechanism: mildly
elevated iron stores enhance hemoglobin synthesis, erythropoiesis, and
oxygen-carrying capacity — a meaningful edge for endurance performance.

Practical Implications

For CC individuals: your HFE protein functions normally. Iron absorption is
properly regulated. No special monitoring or dietary changes are needed.

For CG carriers: you carry one copy of H63D. Your iron absorption may be
mildly increased, but the odds of developing clinically significant iron
overload from this alone are very low. Simple awareness is appropriate — if
iron markers are checked for other reasons, your result is worth noting on
the chart.

For GG homozygotes: you carry two copies of H63D. About 29% of H63D
homozygotes have elevated ferritin, but fewer than 7% develop documented
iron overload. Periodic iron studies are prudent, and you should avoid
unnecessary iron supplementation unless blood tests confirm deficiency.

Interactions

The clinically important interaction is between H63D (rs1799945) and C282Y
(rs1800562). Compound heterozygotes — one copy of each — have a meaningfully
higher risk of iron overload than either variant alone (OR 32 vs OR 5.7 for
H63D/H63D and OR 4.1 for C282Y heterozygotes). About 2% of Europeans are
compound heterozygotes, and roughly 5% of these develop iron overload-related
disease. This combination warrants iron studies monitoring: fasting transferrin
saturation and serum ferritin annually, with referral if transferrin saturation
exceeds 45% or ferritin rises above 300 ug/L (men) or 200 ug/L (women).
This is a strong candidate for a compound implication linking rs1799945 CG/GG
with rs1800562 genotypes.

H63D may also interact with TMPRSS6 (rs855791), which regulates hepcidin
through a different pathway. Carrying iron-increasing alleles in both genes
could have additive effects on iron stores, though this interaction has less
clinical evidence than the HFE C282Y combination.